2d • General discussion
📜 FDA Category 2 & Peptide Access – A Quick Breakdown
What Is Category 2?
FDA classification for bulk drug substances with potential safety risks. Compounding isnot permitted.
19 Peptides Affected (Late 2023)
BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, GHK-Cu (injectable), Melanotan II, CJC-1295, Ipamorelin, Thymosin Alpha-1, and others.
Recent Developments (2026)
Feb 27, 2026 – RFK Jr. Announcement
- Stated ~14 of 19 Category 2 peptides would move back to Category 1
- Called the 2023 reclassification "illegal"
April 15, 2026 – FDA Action
- 12 peptide bulk substances removed from Category 2
- ⚠️ Critical: Removal ≠ authorization to compound
- Peptides remain in regulatory uncertainty
July 23–24, 2026 – PCAC Meeting
FDA committee to discuss adding 7 peptides to the 503A Bulks List:
Day 1 (July 23):
- BPC-157 (ulcerative colitis)
- KPV (wound healing)
- TB-500 (wound healing)
- MOTS-C (obesity, osteoporosis)
Day 2 (July 24):
- Emideltide/DSIP (opioid withdrawal, insomnia)
- Semax (cerebral ischemia, migraine)
- Epitalon (insomnia)
Feb 2027 – Second PCAC Meeting
Cathelicidin (LL-37), GHK-Cu, Dihexa acetate, Melanotan II, PEG-MGF
What This Means for Researchers
- PCAC recommendations are advisory only
- FDA retains final authority
- Rulemaking takes 12–24+ months
- No formal rule change finalized yet
- Access remains primarily through research suppliers
Takeaway
Regulatory process is ongoing. Removal from Category 2 ≠ compounding authorization. PCAC review will shape future access.
⚠️ Research only. Not for human consumption.
0
0 comments
📜 FDA Category 2 & Peptide Access – A Quick Breakdown
powered by
skool.com/biohacking-and-longevity-group-3757
All-in-one peptide education community. 🧪
Dosing guides, storage protocols, stacking frameworks, vendor intel, GLP-1 research, and expert support.🧬
Suggested communities
Powered by